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Abstract
Background: Helical tomotherapy, an advanced intensity-modulated radiation therapy with integrated CT imaging, 
permits highly conformal irradiation with sparing of normal tissue. Capecitabine, a pro-drug of 5-FU that induces 
thymidine phosphorylase can achieve higher levels of intracellular 5-FU when administered concurrently with 
radiation. We evaluated the feasibility as well as the clinical outcome of concurrent administration of capecitabine with 
tomotherapy in patients with advanced pancreatic cancer.
Methods: Nineteen patients with advanced pancreatic cancer including primarily unresectable disease and 
recurrence after curative surgery were included in the study. Two planning target volumes (PTV) were entered: PTV1 is 
gross tumor volume; and PTV2, the volume of the draining lymph nodes. The total doses to target 1 and target 2 were 
55 and 50 Gy, respectively. Capecitabine at 1600 mg/m2/day was administered on each day of irradiation.
Results: Twenty six measurable lesions were evaluated. Overall in-field response rate was 42.3%; partial responses were 
achieved in 53.3% of the pancreatic masses, 28.6% of distant metastatic lesions and 25.0% of regional lymph nodes. 
The median duration of follow-up after tomotherapy was 6.5 months. None of the lesions showed in-field progression. 
Treatment was well tolerated with only minor toxicities such as grade 1 nausea (one patient), grade 1 hand-foot 
syndrome (one patient) and grade 1/2 fatigue (three patients).
Conclusions: Helical tomotherapy with concurrent capecitabine is a feasible option without significant toxicities in 
patients with advanced pancreatic cancer. We achieved excellent conformal distribution of radiation doses and 
minimal treatment-related toxicities with promising target volume responses.
Background
Surgical resection is the standard treatment for localized
non-metastatic pancreatic cancer. Data from the Surveil-
lance Epidemiology and End Results (SEER) registry indi-
ca t e  t ha t  only  a bo ut  10% of  cases  ar e  a ble  t o unde r g o
surgery with curative intent, and only a very small num-
ber of those are cured because of the high incidence of
local relapse and early metastases [1]. Many clinical trials
have been carried out using chemotherapy with or with-
out radiation therapy following curative surgical resec-
tion, with the aim of preventing local and distant
recurrence. With the exception of gemcitabine, neither
chemotherapy nor radiation improved survival [2]. For
those with locally advanced unresectable or metastatic
disease, systemic chemotherapy remains the principal
means of improving survival or alleviating cancer-related
symptoms
The radiation-sensitive structures in the upper abdo-
men (small intestine, stomach, kidneys, liver, and spinal
cord), prevent conventional radiation therapy to the pan-
creas or to the pancreatic bed from delivering adequate
doses, and irradiation is usually accompanied by severe
gastrointestinal intolerance [3]. This may explain in part
the absence of survival benefit in patients with locally
advanced pancreatic cancer who receive radiation ther-
apy alone. However, 5-FU-based concurrent chemoradia-
t i o n  y i e l d s  m o d e s t  s u r v i v a l  b e n e f i t s  i n  p a t i e n t s  w i t h
locally advanced unresectable pancreatic cancer [4,5].
Despite these findings, survival from pancreatic cancer is
still poor, with approximately 23% of patients alive 12
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months following diagnosis, and 5% alive at 5 years [1].
New radiation techniques including intensity modulated
radiation therapy (IMRT), image guided radiation ther-
apy (IGRT) and stereotactic radiosurgery make it possible
to deliver optimally high doses to the target volume with
minimal effect on adjacent radiosensitive tissues [6,7].
Helical tomotherapy is a sophisticated image-guided
IMRT based on the ring gantry concept, employing a
combination of a megavoltage CT scanner and a linear
accelerator [8,9]. Capecitabine, a prodrug of 5-FU, is
absorbed inert from the gastrointestinal tract and selec-
tively metabolized to 5-FU in tumor cells. This selective
conversion achieves higher levels of 5-FU in the tumor
cells than can be obtained by intravenous administration
of 5-FU. Additionally, radiation can magnify the tumor
selectivity of capecitabine by upregulating thymidine
phosphorylase in the tumor cells [10]. Capecitabine also
acts as a radiation sensitizer by disturbing tumor cell
DNA synthesis [11].
In this paper, we report our experience of concurrent
administration of capecitabine with helical tomotherapy
in patients with inoperable or recurrent pancreatic can-
cer. We achieved a highly conformal distribution of radia-
tion doses and minimal treatment-related toxicities with
excellent target volume responses.
Methods
Patient population
Between October 2005 and February 2008, nineteen
patients with pancreatic cancer were treated with concur-
rent chemoradiation using helical tomotherapy and
capecitabine. They included patients with locally
advanced and unresectable disease, and those with local
relapse following curative resection or with metastatic
d i s e a s e .  P a t i e n t s  w h o  w e r e  o l d e r  t h a n  1 8  y e a r s ,  w h o
understood the written informed consent document and
who were willing to sign it, were eligible for inclusion.
The medical records of these patients were reviewed ret-
rospectively. This review was approved by the hospital
institutional ethical committee, and written informed
consent was obtained from each patient.
Radiotherapy
Radiotherapy was provided by helical tomotherapy
(Tomotherapy Incorporated, Madison, WI, USA). Two
planning target volumes (PTV) were entered for each
patient [3]. PTV1 consisted of the gross tumor volume
(GTV) as determined by CT scan, or the tumor bed (in
post-surgical cases). PTV2 consisted of the draining
lymph nodes, comprising the nodes in the porta hepatis,
celiac axis, superior mesenteric and retroperitoneal areas.
PTV2 extended 2 cm below the target volume and did not
have to include the inferior mesenteric nodes. Both tar-
gets were treated simultaneously in 25 daily fractions, 5
days a week. Helical tomotherapy delivered 55 Gy to
PTV1 and 50 Gy to PTV2. In some patients with distant
metastases (liver or lung), the metastatic lesions were also
targeted as another PTV. The distribution of isodoses in
the helical tomotherpy treatment planning is shown in
Figure 1. The dose and volume constraints for the normal
structures are listed in Table 1. Figure 2 is an average
delivered dose-volume histogram for GTV and organ at
risk. Capecitabine (Xeloda; Roche Pharmaceuticals, Nut-
ley, NJ) was given at 1600 mg/m2/day in two doses on
each day of radiation and continued for the duration of
the radiation therapy [3].
Figure 1 Distribution of isodoses in the planning of helical tomotherapy in patients with advanced pancreatic cancer; axial (left), coronal 
(center) and saggital (right) representations. Dose displayed in Gy. The different doses are represented by different colors. Red represents the tar-
get volume dose.Ji et al. Radiation Oncology 2010, 5:60
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Toxicity assessment
Acute toxicity (occurring within 90 days of radiotherapy)
was scored using the National Cancer Institute Common
Toxicity Criteria (NCI CTC), version 2, morbidity scales
[12]. Late toxicity was scored using the Radiation Ther-
apy Oncology Group (RTOG) scale for late toxicity [13].
Patients were evaluated on a weekly basis.
Response assessment
The response of each targeted lesion (defined as the in-
field tumor response) was evaluated by comparing, by the
RECIST criteria, tumor size in pre- and post-treatment
CT images 8 weeks after completion of concurrent
chemoradiation therapy (CCRT). Two different radiolo-
gist evaluated the response rate.
Statistical methods
All statistics are descriptive. Survival was compared using
the Kaplan-Meier method. Statistical analyses were per-
formed using SPSS software, version 15.0, Chicago.
Results
Patient and tumor characteristics
The patient characteristics are shown in Table 2. Twelve
were male and seven were female. Median age was 64.0
(range, 46 - 83). Median duration from diagnosis to
CCRT was 1.5 months (range, 0.2 - 63.3). The patients
were classified with respect to disease status as follows: 1)
eight had primarily unresectable disease without metas-
tasis, and no history of previous treatment, 2) three had
local relapse following complete resection, and 3) eight
Figure 2 Average dose-volume histogram for GTV and organs at risk. Patients were prescribed doses of 55 Gy to PTV1 and 50 Gy to PTV2. GTV = 
gross tumor volume, PTV = planning target volume.
Table 1: Dose and volume constraints for organs at risk.
Structure Maximum dose constraint (Gy) Volume above limit (%) Maximum dose (Gy) Minimum dose (Gy)
Liver 45.00 10.00 52.83 0.30
Right kidney 1.00 1.00 20.60 0.38
Left kidney 15.00 20.00 20.57 0.54
Small bowel 45.00 10.00 53.34 0.18
Stomach 50.00 10.00 52.95 0.44
Duodenum 10.00 1.00 14.07 0.60Ji et al. Radiation Oncology 2010, 5:60
http://www.ro-journal.com/content/5/1/60
Page 4 of 9
had metastatic disease in the liver, lung or peritoneum
(three had metastases on first diagnosis and five had
metastases that developed during the course of disease).
Eight patients had previously received systemic chemo-
therapy.
In-field tumor responses
Twenty six lesions were targeted in nineteen patients
(Table 3). They included 15 pancreatic masses, 4 regional
metastatic lymph nodes and 7 distant metastatic lesions.
Of the 15 pancreatic masses, 8 showed partial responses
(PR, 53.3%) and 7 stable disease (SD, 46.6%). Of the 4
regional metastatic lymph nodes, one showed PR (25.0%)
and three, SD (75.0%). Of the seven distant metastatic
lesions (six hepatic metastases and one pulmonary
metastasis), 2 (a pulmonary lesion and a hepatic lesion)
showed PR (28.6%) and 5, SD (71.4%). Although there
were no complete responses (CR), the overall response
rate was 42.3%. It is of interest that no target lesions
showed in-field progression during the observation
period. Figure 3 illustrates a typical case of a pancreatic
lesion treated with CCRT.
Prognosis and survival
The median duration of follow-up after CCRT was 6.5
months (range, 1.1-17.6, Table 4). The one-year survival
rate was 36.8%, and median survival time was 6.5 months
(range 1.1-21.0). The median survival time in group I
(patients with locally advanced disease without metasta-
ses) was 9.25 months (range, 2-18.4, Table 5). In compari-
son with patients who had locally advanced and
unresectable disease without metastases or a previous
chemotherapy history, the others (those who had metas-
tases at the time of CCRT, and a case with local relapse
Table 2: Patient and tumor characteristics
Patient Sex Age Primary 
tumor site
Previous 
operation
Previous 
chemotherapy
TNM (stage) Duration of follow-up 
after diagnosis 
(months)
Site of 
metastasis
Site of 
tomotherapy
1 F 53 Head No No T4N1M0(IVA) 2.9 Pancreas
2 M 61 Body Yes Gemcitabine #6, 
Cisplatin/
Capecitabine
T3N0M0 (II) 4.9 Pancreas
3 M 67 Tail No No T4N1M0(IVA) 1.5 Pancreas
4 F 76 Body No Gemcitabine #5 T4N1M0(IVA) 7.6 Pancreas
5 M 57 Body No Gemcitabine/
Capecitabine
T4N1M1(IVB) 1.2 Liver Pancreas
6 F 64 Body, tail No No T4N1M0(IVA) 0.2 Pancreas
7 M 67 Body No No T4N1M0(IVA) 1 Pancreas
8 F 71 Body No Gemcitabine/
Cisplatin #3
T3N1M1(IVB) 8 Liver Pancreas
9 M 46 Body, tail No No T4N1M0(IVA) 0.7 Peritoneum Pancreas
10 F 80 Body, tail No No T3N1M0(III) 2.3 Pancreas
11 F 64 Tail No Gemcitabine/
Cisplatin #1
T4N1M1(IVB) 1.3 Liver Pancreas, Liver
12 M 59 Head No No T3N1M1(IVB) 1.4 Liver Pancreas
13 M 68 Body, tail No No T4N1M1(IVB) 0.6 Liver Pancreas, Liver
14 F 54 Neck, body No Gemcitabine/
5 - FU #2
T3N1M0(III) 5.5 Pancreas
15 M 57 Body Yes Gemcitabine, 
Cisplatin/5 FU 
#6
T4N1M1(IVB) 5.2 Liver Pancreas
16 M 83 Head No No T4N1M0(IVA) 0.2 Pancreas
17 M 54 Head No No T4N1M0(IVA) 0.2 Pancreas
18 M 64 Yes Gemcitabine/
xeloda #9, 
Irinotecan #2
M1(IVB) 63.3 Lung Lung
19 M 58 Head No No T4N1M0(IVA) 2.4 PancreasJi et al. Radiation Oncology 2010, 5:60
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Page 5 of 9
after previous curative surgery as well as those with a his-
tory of previous chemotherapy) showed poor survival (p
= 0.063); 4.4 months (range, 1.1-21) versus 12.55 months
(range, 6.5-18.4). Of the patients in group I, those who
had no history of previous chemotherapy survived better
than those with a history of previous chemotherapy (p =
0.0009); 12.55 months (range, 6.5-18.4) versus 3.9 months
(range, 2-5.8).
Progression of disease outside the targeted tumor vol-
ume (defined as the out-field progression) occurred in 7
patient. The median time to out-field progression was 3.8
months (range 2.2-7.3) with or without systemic chemo-
therapy following CCRT.
Toxicity
Acute toxicity is summarized in Table 6. As shown, only
minor toxicities developed. The most common acute tox-
icity was grade 1 or 2 fatigue that occurred 2 to 3 weeks
after the start of tomotherapy (three patients, 16.7%).
Intriguingly, no treatment was interrupted due to gastro-
intestinal side effects. Only grade 1 nausea developed in
one patient (5.6%). Grade 1 hand-foot syndrome related
to oral capecitabine also developed in one patient (5.6%).
None experienced hematologic toxicities during the
treatment. All toxicities were manageable medically and
regressed spontaneously, and they did not interfere with
the scheduled radiotherapy. There were no treatment-
related deaths and no grade 3 or 4 toxicity. Therefore,
treatment was well tolerated by all patients.
Discussion
The majority of pancreatic cancer patients have advanced
disease at the time of diagnosis due to a lack of symptoms
and signs. Without treatment, mean survival time is 4-6
months and overall 5-year survival remains less than 5%.
[14]. The only curative option is surgery, but only 10-20%
of patients have tumors appropriate for radical resection
[15]. Advanced pancreatic cancer is generally incurable
and all therapies have significant limitations. The
response to systemic chemotherapy is poor, with an
approximately 20% response rate. The conventional radi-
ation dose to the tumor volume is not large enough to
cure patients because pancreatic tumors move markedly
as patients breathe, and are surrounded by the duode-
Table 3: In-field tumor response rates of the target lesions 
after tomotherapy and concurrent capecitabine treatment
Target lesions CR PR SD PD
Pancreatic mass (n = 15) 0 (0) 8 (53.3) 7 (46.7) 0 (0)
Regional lymph nodes (n = 4) 0 (0) 1 (25.0) 3 (75) 0 (0)
Distant metastasis (n = 7) 0 (0) 2 (28.6) 5 (71.4) 0 (0)
Liver (n = 6) 0 (0) 1 (16.7) 5 (83.3) 0 (0)
Lung (n = 1) 0 (0) 1 (100) 0 (0) 0 (0)
Overall (n = 26) 0 (0) 11 (42.3) 15 (57.7) 0 (0)
CR, complete response; PR, partial response; SD, stable disease; PD, 
progressive disease
Numbers in parentheses are percentages
Figure 3 Abdomenal CTs before (left) and after (right) helical tomotherapy with concurrent capecitabine. Two months after helical tomother-
apy the volume of the pancreatic tumor is significantly reduced.Ji et al. Radiation Oncology 2010, 5:60
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num, which is the dose-limiting organ [16]. Compared
with chemotherapy alone or radiotherapy alone, chemo-
radiotherapy prolongs median survival somewhat, to
approximately 9-12 months, in those with locally
advanced unresectable disease [5].
Helical tomotherapy, a new radiotherapy system, is a
helical IMRT with integrated CT imaging, offering highly
conformal radiation with normal tissue sparing. The basis
of image guidance is utilizing daily images gained in the
treatment position in order to visualize daily organ varia-
tions and setup errors [17-19]. The radiation is dis-
charged as a fan beam by a linear accelerator mounted on
a turning gantry and is adjusted by a rapid pneumatically
driven binary slit collimator [20]. The speed of gantry
rotation and table movement is uniform for the entire
fraction. Hence helical tomotherapy can provide signifi-
cant conformal dose distributions at numerous locations
[21-24].
Helical tomotherapy can treat multiple lesions more
rapidly than conventional radiotherapy, for which multi-
ple target points are necessary [20]. Moreover it is an
ideal device for delivering multifocal, high-dose radiation
without a significant increase in toxicity [9,25]. Thus it
allows us to treat patients with multiple targets including
metastatic lesions.
The ideal concurrent chemotherapeutic agent in the
therapy of pancreatic cancer should have both a systemic
effect and radiosensitizing properties [16]. Capecitabine
has a pronounced radiosensitizing effect on tumor cells
such that DNA strand breakage induced by radiation is
more difficult to repair [11]. The regimen described here
takes advantage of the tumor-selective ability of capecit-
abine to enhance radiation effects within the tumor but
not in the surrounding normal tissues. This can be
ascribed to a higher 5-FU concentration in tumor cells
and the induction of thymidine phosphorylase by the
Table 4: Clinical outcomes in the nineteen patients treated with tomotherapy and concurrent capecitabine
Patient Overall In-field 
tumor response
Duration of 
tumor response 
(months)
Treatment-related 
toxicity
Duration of 
follow-up after 
tomotherapy 
(months)
Out-field 
progression 
state
Cause of death 
other than cancer 
progression
Duration of 
survival after 
tomotherapy 
(months)
1 Stable disease 5.9 fatigue (grade 2) 7.3 Progressed 7.3
2 Partial response hand foot syndrome 
(grade 1)
3.2 4.8
3S t a b l e  d i s e a s e 1 0 . 7 1 1 . 2
4 Stable disease 3.8 5.8 Progressed 5.8
51 . 1 P n e u m o n i a 1 . 1
6 Partial response fatigue (grade 2) 6.8 13.9
7 Stable disease 6.9 15 Progressed 16.3
81 . 8 1 . 9
9 Partial response 2.4 nausea (grade 1) 4.4 Progressed 4.4
10 Partial response 13.6 13.9
11 Stable disease 4.1 fatigue (grade 1) 4.1 Stable 
disease
Pulmonary 
thromboembolis
m
4.1
12 Stable disease 2.2 3.4 Progressed 3.9
13 Stable disease 2.5 6.5 Progressed 6.5
14 2 DUB, Pneumonia 2
15 Stable disease 10.5 10.5
16 Partial response 7.3 7.3 Stable 
disease
Pneumonia 7.3
17 Partial response 14.9 18.4
18 Partial response 17.6 21
19 Partial response 3.2 6.2 Progressed 6.5
DUB, duodenal malignant ulcer bleedingJi et al. Radiation Oncology 2010, 5:60
http://www.ro-journal.com/content/5/1/60
Page 7 of 9
irradiation [10]. Also, the use of capecitabine is attractive
because it is absorbed as an inert drug, causing little
direct toxicity in the gastrointestinal tract.
Ben-Josef et al [3] treated 15 patients with unresectable
or recurrent pancreatic cancer with IMRT and concur-
rent capecitabine. In that study, the regimen was well tol-
erated without significant toxicities, and efficacy was
encouraging.
Another basis for offering radiotherapy to patients with
pancreatic cancer is palliation of symptoms due to local
invasion, such as biliary and gastrointestinal obstruction
[26]. The drawbacks of radiotherapy include the acute
and chronic toxicities of radiotherapy, particularly when
the indication is palliation. Because of its ability to
restrict the dose to normal organs and minimize radia-
tion toxicities, helical tomotherapy may be an ideal pallia-
tive option for challenging cases of pancreatic cancer
[27].
In our study, the overall in-field tumor response rate
was 42.3%. Previous studies have reported 10-50%
response rates for locally advanced pancreatic cancer
with chemoradiotherapy [28-32]. The high response rate
in our study is due to in-field assessment of responses.
Considering the advanced stage of our patients, the in-
field response rate is encouraging. It may be possible to
increase this response rate by increasing the dose of
capecitabine.
It may be noted that helical tomotherapy with concur-
rent capecitabine yielded excellent disease control within
the radiation field, with an in-field disease control rate of
essentially 100%. This could be thought to be a significant
therapeutic benefit.
Median overall survival after tomotherapy was only 6.5
months. This was because of advanced stages of our
study population (tumor stages III or IV). Our study
included patients with locally advanced disease, local
relapse following complete resection, and metastases.
Patients who had locally advanced disease without
metastasis or a previous history of chemotherapy showed
a tendency to survive longer than the others (12.55 versus
4.4 months) after tomotherpy. In our opinion, tomother-
a p y  w i t h  c o n c u r r e n t  c a p e c i t a b i n e  s h o u l d  b e  t h e  f i r s t
option for inoperable pancreatic cancer, especially in
patients without metastases or a previous history of che-
motherapy.
Although our patients were elderly, with a median age
of 64, treatment was well tolerated. The majority of treat-
ment-related toxicities were mild and transient. Only
grade 1/2 fatigue, nausea and hand-foot syndrome devel-
oped, and they subsided with symptomatic care and with-
out prematurely stopping radiotherapy. There was no
direct treatment-related grade 3/4 toxicity or death.
Therefore helical tomotherapy is a safe option in the
treatment of advanced pancreatic cancer.
This study had several limitations. First, the number of
cases was low. Second, the heterogeneity of the study
po p u la t i o n  m a d e  d i r ect  c o m pa ri so n  wi t h  o t h e r  s t u d i es
difficult. Third, long term treatment effects and late tox-
icities remain to be evaluated because the median follow-
up time in our study was relatively short.
Although there was no in-field progression during the
observation period, out-field progression occurred in
seven patients. This observation provides a rationale for
follow-up systemic chemotherapy after tomotherapy to
Table 5: Survival of pancreatic cancer patients treated with tomotherapy and concurrent capecitabine
Group Characteristics Median duration of survival (months)
I Locally advanced without metastasis (n = 10) 9.25 (2.00-18.4)
No previous chemotherapy (n = 8) 12.55 (6.50-18.4)
Previous chemotherapy (n = 2) 3.90 (2.00, 5.8)
II Locally relapsed without metastasis following complete resection (n = 1) 4.80 (4.80)
III Metastatic disease (n = 8) 4.25 (1.10-21.00)
De novo (n = 3) 4.40 (3.90-6.50)
Relapsed (n = 5) 4.10 (1.10-21.00)
Data in parentheses are ranges of survival times
Table 6: Treatment-related toxicity
Grade 1 Grade 2
Fatigue 1 (5.6) 2 (11.1)
Nausea 1 (5.6) 0 (0)
Hand-foot syndrome 1 (5.6) 0 (0)
Data in parentheses are percentagesJi et al. Radiation Oncology 2010, 5:60
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prevent or delay out-field progression. Hence, subsequent
chemotherapy such as gemcitabine alone or erlotinib
combined with gemcitabine should be performed in eligi-
ble patients [33,34].
There are only two examples of the clinical application
of helical tomotherapy for locally advanced pancreatic
cancer [35]. To the best of our knowledge, this is first
comprehensive analysis of the clinical application of heli-
cal tomotherapy for a group of inoperable or recurrent
pancreatic cancers.
Conclusions
Our study demonstrates that helical tomotherapy with
concurrent capecitabine is a feasible and safe option for
locally advanced unresectable or metastatic pancreatic
cancer. Our preliminary data yielded a high local control
rate. Because of its ability to irradiate multiple targets
simultaneously, helical tomotherapy could be an ideal
palliative option for challenging cases of pancreatic can-
cer with metastases. Further large scale clinical trials are
needed to verify the efficacy and safety of helical tomo-
therapy with concurrent capecitabine for treating
advanced pancreatic cancer. Also, careful selection of
those patients that stand to benefit from this regimen is
needed.
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